Prenetics Crosses a Line: Free Cash Flow Positive, $1B Backing, and a $400M 2027 Ambition

IM8's explosive growth and General Catalyst funding turn the page from investment to payback.

PRE · Earnings Call · 2026-08-18

The Free Cash Flow Inflection

Prenetics' Q2 2026 earnings call was anything but routine. In a first-ever live webcast, CEO Danny Yeung opened the books with a 40-page shareholder letter and an 80-page investor deck, and for good reason: the company crossed a threshold it had targeted since day one.

Last month, we crossed it. In July, our consolidated adjusted free cash flow, and I want to be precise here because precision is the whole point of today, that measure includes the funding under our general Countless facility turned positive for the first time in our history.
Sheng Wu Yeung · 2026-08-18

The inflection was driven by a record July: $20.9 million in revenue (4.3x year-over-year), a record cohort of 47,373 new customers, and a customer acquisition cost that fell 21% sequentially to $239. The company is now guiding to its first positive adjusted free cash flow quarter in Q3, a dramatic shift from the investment-heavy posture of the past. This moment wasn't improvised. Danny noted, "We say what we'll do. And then when we do it, I want to own that pattern in front of you." “We say what we'll do. And then when we do it, I want to own that pattern in front of you.” — Sheng Wu Yeung · 2026-08-18 The underlying arithmetic is now visible: every dollar spent on acquisition has returned $1.52 of lifetime gross profit, and that figure is still climbing as more cohorts mature. “Every acquisition dollar that we've spent has generated $1.52 of gross profit in our life cycle of our business.” — Brian Rosin · 2026-08-18

A $1 Billion Backing

The fuel for this growth comes from an unusual source: a $1 billion commitment from General Catalyst. The deal, announced a month ago, was underwritten after months of deep diligence into every cohort at the transaction level. This is not a typical growth-equity check; it is a syndicated facility that funds 70% of the company's acquisition marketing spend on the way in. As CFO Brian Rosin explained, the structure effectively removes the cash constraint on growth. "We'll still end up generating quite a bit of adjusted free cash flow positive momentum into future quarters." The company also raised its full-year revenue guidance to $220–230 million, with IM8 contributing $215–222 million, and initiated 2027 guidance of $400 million or more. That math is underwritten by 140,000 active subscribers and a retention curve that outperforms direct competitors like Thorne and AG1 at month 20. The General Catalyst partnership is a strategic pivot from the company's previous model of self-funding growth. It also changes the narrative around the balance sheet: with $109.4 million in cash and current financial assets, plus the facility, the company can continue scaling aggressively without dilutive equity raises.

Product Expansion and Science

The growth engine isn't just one product. IM8's IM8 revenue hit $45 million in Q2, and the company is already teeing up two new categories: IM8 hydration in Q4 and a gummy line in Q1 2027. These are backed by the same rigorous clinical approach that has defined the brand. Mayo Clinic is running a randomized placebo-controlled trial on the daily essentials, and two other studies are underway for longevity and gut health. The company is investing millions into evidence generation, a rarity in the supplement space where most brands rely on marketing claims. As Chief Medical Officer Dr. Dawn Mussallem put it, the goal is to make IM8 the product physicians recommend—and it's already stocked in Mayo Clinic's pharmacy. The Scientific Advisory Board is a core asset, and the company's cohort math continues to improve. The AI-native organization—just 70 people generating over $3 million in revenue per employee—is a model that scales without proportional headcount growth.

The Path to 2027

This quarter also marked a transition in how the market should evaluate the company. The previous guidance of a $15–20 million EBITDA loss (as Danny stated in May) is being replaced by a trajectory toward profitability. The company now expects adjusted EBITDA losses to narrow to $8–12 million in H2 2026, with a clear path to breakeven by end of 2027. But the real signal is the confidence in the revenue outlook: "We'll exit the year above $300 million run rate before a single '27 customer walks into the door." The competitive landscape is shifting too. While peers like Huel, Gruns, and Thorne have been acquired at premium multiples, Danny reminded investors that he's building for the long term: "We are building IM8 not to get acquired." The company's unique mix of science, brand affinity, and unit economics—now backed by a $1 billion war chest—makes it a rare standalone asset in the consumer health sector. All told, Prenetics has crossed its most critical financial milestone, and the market is only beginning to price in the 2027 trajectory. Marketing spend is still running at 78% of sales in Q2, but with CAC falling and monthly revenue compounding, the flywheel is turning. This is a name to watch.